Physician profile
Scott Middleton
NPI 1497742621
$14,640.34
in general payments reported to CMS, 2019-2025
37 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,649 · 2020: $1,405 · 2021: $3,665 · 2022: $2,141 · 2023: $1,757 · 2024: $1,017 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966 · Honoraria: $700 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.83 |
| Honoraria | $700.00 |
| Education | $114.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,579.35 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,480.00 | 2019-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,410.97 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,030.03 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $1,004.83 | 2019-2022 | |
| Glaxosmithkline, LLC. | $941.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Abbvie INC. | $927.94 | 2019-2025 | |
| Amgen INC. | $823.36 | 2019-2023 | Otezla, Repatha |
| Astellas Pharma US INC | $809.70 | 2019-2024 | Veozah, Myrbetriq |
| Becton, Dickinson and Company | $700.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $625.98 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $571.00 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $467.41 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $360.49 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $331.17 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $307.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $201.92 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.06 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $139.57 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.13 | 2019-2024 | Trulance, Xifaxan |
| Radius Health, INC. | $126.77 | 2019 | |
| Antares Pharma, INC. | $91.21 | 2019-2022 | |
| Therapeuticsmd, INC. | $69.70 | 2019 | |
| Promius Pharma LLC | $41.92 | 2019 | |
| Phathom Pharmaceuticals, INC. | $39.54 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $39.28 | 2020 | |
| Boston Scientific Corporation | $38.50 | 2021 | |
| Optos, INC. | $35.28 | 2021 | |
| Sumitomo Pharma America, INC. | $28.96 | 2023 | Gemtesa |
| Shire North American Group INC | $21.72 | 2019 | |
| Sobi, INC | $21.40 | 2019 | |
| Lundbeck LLC | $21.34 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $19.76 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.03 | 2024 | Quviviq |
| Adlon Therapeutics L.P. | $14.58 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.88 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Middleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.